ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.62
-0.18 (-2.31%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous close7.80
Open7.71
Bid7.51 x 1200
Ask8.07 x 800
Day's range7.50 - 7.99
52-week range5.08 - 10.44
Volume3,411
Avg. volume8,136
Market cap209.561M
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)-0.31
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, announced today the presentation of two posters on varlitinib at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, from 19 to 23 September 2018. Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed by ASLAN across multiple indications including a global pivotal trial in biliary tract cancer and a global study in gastric cancer. Poster title: Multicenter Phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.

  • GlobeNewswire8 days ago

    ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced an update to its planned timelines for the ongoing single-arm clinical trial in China testing varlitinib plus capecitabine in patients with advanced or metastatic biliary tract cancer (BTC). In the interim, ASLAN will continue to recruit patients into the study and provide a further update on study timelines in early 2019. ASLAN’s global pivotal study in second line BTC, TREETOPP, remains on track to complete patient enrolment in early 2019.

  • GlobeNewswire21 days ago

    ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced its participation at the HC Wainwright 20th Annual Global Investment Conference. Dr Carl Firth, Chief Executive officer, is scheduled to present an overview of the company on Wednesday, 5 September 2018 at 10:00am ET. A live audio webcast of the presentation will be available via http://wsw.com/webcast/rrshq28/asln/ with an archived replay link available in the Investors section of ASLAN’s website at www.aslanpharma.com following the event.

  • GlobeNewswirelast month

    ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the US Food and Drug Administration (FDA) has granted ASLAN003 Orphan Drug Designation (ODD) as a treatment for acute myeloid leukaemia (AML). ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in AML. AML is a cancer of the myeloid line of blood cells, characterised primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells.

  • GlobeNewswirelast month

    ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer

    ASLAN Pharmaceuticals (ASLN) (TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the completion of recruitment of 52 patients for the phase 2 part of its global phase 2/3 study investigating varlitinib as first line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients. Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed by ASLAN across multiple indications including a global pivotal trial in biliary tract cancer. Initiated in 2017, the global phase 2/3 study is a double blind, randomised two-arm study that aims to determine the efficacy of varlitinib in combination with mFOLFOX6 (a combination chemotherapy regimen) in comparison to mFOLFOX6 alone in the first line setting.

  • GlobeNewswire2 months ago

    ASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    SINGAPORE, Aug. 06, 2018-- ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, ...

  • GlobeNewswire3 months ago

    ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004

    SINGAPORE, July 03, 2018-- ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company based in Asia developing novel therapeutics for global markets, today announced the submission of a clinical ...